Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Arylaminopyrimidine compound and use thereof and pharmaceutical composition and medicinal composition prepared from arylaminopyrimidine compound

A technology for arylaminopyrimidines and compounds, which can be used in drug combinations, medical preparations containing active ingredients, organic chemistry, etc., and can solve problems such as intolerable toxicity

Active Publication Date: 2015-08-26
SHANGHAI HAIYAN PHARMA TECH +1
View PDF3 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The concentration required to inhibit the growth of drug-resistant cells is much higher than that of normal cells, and the toxicity is often unacceptable at this dose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Arylaminopyrimidine compound and use thereof and pharmaceutical composition and medicinal composition prepared from arylaminopyrimidine compound
  • Arylaminopyrimidine compound and use thereof and pharmaceutical composition and medicinal composition prepared from arylaminopyrimidine compound
  • Arylaminopyrimidine compound and use thereof and pharmaceutical composition and medicinal composition prepared from arylaminopyrimidine compound

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0173] Preparation of 3-amino-6-morpholinopyridine

[0174]

[0175] step 1:

[0176] At room temperature, 2-bromo-5-nitropyridine (2 g, 10 mmol) was added to 10 ml of morpholine solution, and vigorously stirred at room temperature for 4 hours. After the reaction, a yellow solid precipitated out. After filtration, the yellow solid was washed with 50 mL petroleum ether to give 4-(5-nitropyridin-2-yl)morpholine (1.9 g, 92%). Spectral data: MS m / z (ESI): 210.1 [M+H] +

[0177] Step 2:

[0178] At room temperature, palladium on carbon (100 mg, 10% wt) was added to 4-(5-nitropyridin-2-yl) morpholine (1 g, 9.1 mmol) in 60 ml of methanol solution, vigorously stirred at room temperature under a hydrogen atmosphere 20 hours. After the reaction, the palladium carbon was filtered off, and the filtrate was concentrated under reduced pressure to obtain the product 3-amino-6-morpholinylpyridine, which was directly used in the next reaction. Spectral data: MS m / z (ESI): 180.1 [M...

Embodiment 1

[0291] N-(3-(3-(2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin4-yl)ureido)phenyl)propene Preparation of amides (cpd-1)

[0292]

[0293] Step 1: Synthesis of 2-chloro-4-pyrimidine isocyanate

[0294] At 0 degrees Celsius, 4-amino-2-chloropyrimidine (4.8g, 37.0mmol) was added to a solution of triphosgene (5.5g, 18.5mmol) in 200ml of tetrahydrofuran (THF), and then N,N- - Diisopropylethylamine (DIEA) (6.23 g, 48.2 mmol). Stir vigorously at room temperature for 4 hours. The progress of the reaction was detected by TLC. After the substrate was completely reacted, the product 2-chloro-4-pyrimidine isocyanate was directly used in the next reaction.

[0295] Step 2: Synthesis of 1-(2-chloropyrimidin-4-yl)-3-(3-nitrophenyl)urea

[0296] At room temperature, triethylamine (TEA) (11 g, 110 mmol) and 3-nitroaniline (5.6 g, 40.3 mmol) were added to a solution of 2-chloro-4-pyrimidine isocyanate (5.7 g, 36.6 mmol) in 200 ml of THF , stirred vigorously at room temper...

Embodiment 2

[0303] N-(3-(3-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)ureido)phenyl)acrylamide (cpd-2 ) preparation

[0304]

[0305] Step 1: Synthesis of 1-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-3-(3-nitrophenyl)urea

[0306] 4-(4-Methylpiperazin-1-yl)aniline (392 mg, 2.00 mmol) and trifluoroacetic acid (700 mg, 6.0 mmol) were added to 1-(2-chloropyrimidin-4-yl)-3-( 3-Nitrophenyl)urea (600mg, 2.00mmol) in 14ml of n-butanol was stirred vigorously at 130°C for 7 hours. After the reaction, the system was cooled to room temperature and filtered to obtain a brown solid. Wash the brown solid with 50 ml of ethanol to give compound 1-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-3-(3-nitro Phenyl)urea (500 mg), the product was used directly in the next step. Yield: 56%, purity: 72%, spectral data: MS m / z (ESI): 449.2 [M+H] +

[0307] Step 2: Synthesis of 1-(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-3-(3-aminophenyl)urea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are an arylamino pyramidine compound having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvent compound, or prodrug of said arylamino pyramidine compound; also provided are pharmaceutical compositions and pharmaceutically acceptable compositions containing the arylamino pyramidine compound, and applications thereof.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an arylaminopyrimidine compound and its application as an EGFR tyrosine kinase inhibitor, as well as a pharmaceutical composition and a pharmaceutical composition prepared therefrom. Background technique [0002] Lung cancer is the cancer with the highest incidence rate in the world. The incidence rate of lung cancer in China ranks first among all cancers. The mortality rate exceeds 3 / 10000; and the number of cases is increasing year by year. In addition, China's air pollution is serious, and the high level of PM2.5 will lead to a higher incidence of lung cancer in the future. [0003] Among Chinese lung cancer patients, 30% of patients have EGFR mutations, among which L858R and exon 19 deletion mutations account for more than 90%. Such patients have higher EGFR activity after mutation, and patients are more sensitive to EGFR inhibitors. The first-generation EGFR inhibitors alr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/48C07D401/12C07D401/14C07D239/42A61K31/506A61K31/5377A61P35/00A61P3/10A61P37/02A61P25/00A61P9/00
CPCA61K31/505A61K31/506A61K31/5377C07D239/42C07D239/48C07D401/12C07D401/14A61P3/10A61P9/00A61P25/00A61P35/00A61P37/02
Inventor 兰炯崔玉敏张亮金云舟周福生程鹏飞
Owner SHANGHAI HAIYAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com